Seeing Is Believing
Currently out of the existing stock ratings of Srikripa Devarakonda, 33 are a BUY (100%).
Analyst Srikripa Devarakonda, currently employed at TRUIST, carries an average stock price target met ratio of 19.44% that have a potential upside of 27.7% achieved within 81 days.
Srikripa Devarakonda’s has documented 69 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KYMR, Kymera Therapeutics at 01-Nov-2024.
Analyst best performing recommendations are on KYMR (KYMERA THERAPEUTICS).
The best stock recommendation documented was for KYMR (KYMERA THERAPEUTICS) at 11/3/2023. The price target of $41 was fulfilled within 112 days with a profit of $26.73 (187.32%) receiving and performance score of 16.72.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$74
$2.28 (3.18%)
$80
7 days ago
(19-Nov-2024)
27/39 (69.23%)
$5.55 (8.11%)
202
Hold
$69
$-2.72 (-3.79%)
$64
27 days ago
(30-Oct-2024)
19/20 (95%)
$-4.93 (-6.67%)
154
Hold
$71
$-0.72 (-1.00%)
$65
27 days ago
(30-Oct-2024)
6/7 (85.71%)
$-2.93 (-3.96%)
108
Hold
$70
$-1.72 (-2.40%)
$65
27 days ago
(30-Oct-2024)
5/11 (45.45%)
$-3.93 (-5.32%)
119
Hold
$68
$-3.72 (-5.19%)
$62
27 days ago
(30-Oct-2024)
3/5 (60%)
$-5.93 (-8.02%)
28
Which stock is Srikripa Devarakonda is most bullish on?
Which stock is Srikripa Devarakonda is most reserved on?
What Year was the first public recommendation made by Srikripa Devarakonda?